Today: 14 June 2026
Browse Category

NASDAQ:GMAB 30 December 2025 - 8 May 2026

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
31 December 2025
···
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus N.V. shares were halted Tuesday after Nasdaq confirmed Genmab’s $97-a-share cash acquisition closed, with trading set for suspension Dec. 31. Holders will receive $97 per share minus a $10.67 Dutch dividend withholding tax, leaving about $86.33 before any refund. Merus requested delisting, and two directors resigned as the merger became effective. Genmab’s U.S. shares fell about 2% in late-morning trading.
30 December 2025
··

Stock Market Today

  • GHCL Limited to Trade Ex-Dividend on June 18 with ₹12 Dividend Payment
    June 13, 2026, 11:31 PM EDT. GHCL Limited (NSE:GHCL) will trade ex-dividend on June 18, meaning shareholders must purchase shares before this date to qualify for the upcoming dividend payout of ₹12 per share on July 25. The stock currently trades at ₹430.45, offering a trailing dividend yield of approximately 2.8%. GHCL's dividend payout ratio is conservatively low at 24% of its profit after tax and covers just 27% of its free cash flow, indicating sustainable dividend payments. Additionally, the company has demonstrated a 10% average annual growth in earnings per share over the past five years, supporting future dividend increases and business growth.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop